Of note, mTOR inhibitor temsirolimus has also demonstrated evidence of HIF-1α inhibition, and a clinical trial combining temsirolimus with bevacizumab and liposomal doxorubicin demonstrated extensive anti-tumor activity in multiple tumor types [44]. The gene discussed is HIF1A; the disease is neoplasm.